RNAM Earnings
Avidity Biosciences Inc
1W: -1.9%
1M: -1.7%
YTD: -1.8%
$72.86
Last traded 2026-03-03 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Last Earnings
2026-02-23
EPS
$-1.59
▼ Miss -22.6%
Revenue
$860K
▼ Miss -73.7%
Next Earnings
Qtr ending 2026-12-31 · date TBD
EPS Estimate
$-1.41
Range: $-1.41 - $-1.41
Revenue Estimate
$5M
4 analysts
Estimate vs Actual
Earnings Surprise History
0/1
EPS Beats
0/1
Revenue Beats
0%
EPS Beat Rate
0%
Rev Beat Rate
Wall Street Forward Estimates
Quarterly
Annual
Estimate Revisions
Recent Revisions
| Date | Period | Fiscal Date | EPS Old | EPS New | Change | Rev Old | Rev New |
|---|---|---|---|---|---|---|---|
| 2026-03-04 | annual | 2029-12-31 | $— | $6.16 | ▲ 6.16 | $— | $2,317,000,000 |
| 2026-03-04 | annual | 2028-12-31 | $— | $0.09 | ▲ 0.08 | $— | $1,402,100,000 |
| 2026-03-04 | annual | 2027-12-31 | $— | $-3.79 | ▼ 3.79 | $— | $337,967,647 |
| 2026-03-04 | annual | 2026-12-31 | $— | $-5.19 | ▼ 5.19 | $— | $17,730,424 |
| 2026-03-04 | annual | 2025-12-31 | $— | $-4.57 | ▼ 4.57 | $— | $21,535,079 |
| 2026-03-04 | annual | 2024-12-31 | $— | $-2.87 | ▼ 2.87 | $— | $9,740,500 |
| 2026-03-04 | quarter | 2026-12-31 | $— | $-1.41 | ▼ 1.41 | $— | $4,850,000 |
| 2026-03-04 | quarter | 2026-09-30 | $— | $-1.39 | ▼ 1.39 | $— | $2,370,600 |
| 2026-03-04 | quarter | 2026-06-30 | $— | $-1.32 | ▼ 1.32 | $— | $1,769,400 |
| 2026-03-04 | quarter | 2026-03-31 | $— | $-1.29 | ▼ 1.29 | $— | $1,769,400 |
| 2026-03-04 | quarter | 2025-12-31 | $— | $-1.30 | ▼ 1.30 | $— | $3,265,793 |
| 2026-03-04 | quarter | 2025-09-30 | $— | $-1.09 | ▼ 1.09 | $— | $1,937,014 |
| 2026-03-04 | quarter | 2025-06-30 | $— | $-0.96 | ▼ 0.96 | $— | $1,490,233 |
| 2026-03-04 | quarter | 2025-03-31 | $— | $-0.88 | ▼ 0.88 | $— | $2,367,160 |
| 2026-03-04 | quarter | 2024-12-31 | $— | $-0.79 | ▼ 0.79 | $— | $1,633,333 |
Earnings Call Transcripts
No transcripts available.